A physician survey on the application of the British Society for Haematology guidelines for the diagnosis and management of myelofibrosis in the UK

Br J Haematol. 2020 Mar;188(6):e105-e109. doi: 10.1111/bjh.16390. Epub 2020 Feb 19.

Authors

Claire N Harrison¹, Adam J Mead^{2

3}, Mark W Drummond⁴, Gavin Chiu⁵, Rozinder Bains⁵

Affiliations

¹ Department of Haematology, Guy's and St. Thomas' NHS Foundation Trust, London, UK.
² MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.
³ NIHR Oxford Biomedical Research Centre, John Radcliffe Hospital, Oxford, UK.
⁴ Beatson Cancer Centre, University of Glasgow, Glasgow, UK.
⁵ Novartis Pharmaceutical UK Ltd, Camberley, UK.

PMID: 32077091
DOI: 10.1111/bjh.16390

No abstract available

Keywords: diagnostic haematology; myelofibrosis; therapy.

Publication types

Guideline
Research Support, Non-U.S. Gov't

MeSH terms

Hematology
Humans
Physicians
Primary Myelofibrosis / diagnosis*
Primary Myelofibrosis / therapy*
Surveys and Questionnaires
United Kingdom

Grants and funding